Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Gross Margin (2018 - 2025)

BioNexus Gene Lab's Gross Margin history spans 8 years, with the latest figure at 14.85% for Q3 2025.

  • For Q3 2025, Gross Margin rose 243.0% year-over-year to 14.85%; the TTM value through Sep 2025 reached 14.77%, up 131.0%, while the annual FY2024 figure was 13.56%, 5.0% down from the prior year.
  • Gross Margin for Q3 2025 was 14.85% at BioNexus Gene Lab, down from 16.28% in the prior quarter.
  • Across five years, Gross Margin topped out at 136.82% in Q1 2021 and bottomed at 7.65% in Q2 2021.
  • The 5-year median for Gross Margin is 13.88% (2023), against an average of 20.23%.
  • The largest YoY upside for Gross Margin was 11547bps in 2021 against a maximum downside of -220513bps in 2021.
  • A 5-year view of Gross Margin shows it stood at 16.29% in 2021, then fell by -27bps to 11.95% in 2022, then fell by -2bps to 11.73% in 2023, then rose by 4bps to 12.25% in 2024, then increased by 21bps to 14.85% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Gross Margin are 14.85% (Q3 2025), 16.28% (Q2 2025), and 16.07% (Q1 2025).